An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).
Inclusion Criteria:
Exclusion Criteria:
New York, New York 10032, United States
Alberdi Sur, X5003DCE, Argentina
C.a.b.a, 1056, Argentina
Providencia, Santiago de Chile, 7500691, Chile
Essen, 45239, Germany
Aichi, Seto, 489-8642, Japan
Fukuoka, Kurume, 830-0011, Japan
Hyogo, Himeji, 670-8520, Japan
Hyogo, Kobe, 650-0047, Japan
Kanagawa, Yokohama, 236-0051, Japan
Kumamoto, Kumamoto, 861-4193, Japan
Miyagi, Sendai, 980-8574, Japan
Osaka, Sakai, 591-8555, Japan
Osaka, Takatsuki, 569-8686, Japan
Shizuoka, Hamamatsu, 431-3192, Japan
Tokushima, Tokushima, 770-8503, Japan
Tokyo, Bunkyo-ku, 113-8519, Japan
Tokyo, Minato-ku, 105-8470, Japan
Tokyo, Shinjuku-ku, 162-8655, Japan